Hemodynamics in the isolated cirrhotic liver

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 3, 2007, Pages

  Zipprich, Alexander ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cirrhosis; Hepatic arterial vascular resistance; Intrahepatic vascular resistance; Portal hypertension

Indexed keywords

ADENOSINE; ENDOTHELIN 1; FLURBIPROFEN 4 NITROXYBUTYL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NCX 1000; NITRIC OXIDE; NITRIC OXIDE DONOR; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID DERIVATIVE; VASOCONSTRICTOR AGENT;

ARTERY RESISTANCE; BLOOD VESSEL TONE; CONFERENCE PAPER; FUNCTIONAL ANATOMY; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER SINUSOID; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ADENOSINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; ENDOTHELIN-1; HEMODYNAMICS; HEPATIC ARTERY; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRCULATION; LIVER CIRRHOSIS; NITRIC OXIDE; PORTAL PRESSURE; PROSTAGLANDINS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 35848932269     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318150d3b5     Document Type: Conference Paper

References (61)

1. Gupta TK, Toruner M, Groszmann RJ. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide. Digestion. 1998;59:413-415.
2. Lautt WW, Greenway CV, Legare DJ, et al. Localization of intrahepatic portal vascular resistance. Am J Physiol. 1986;251:G375-G381.
3. Ayuse T, Brienza N, O'Donnell CP, et al. Pressure-flow analysis of portal vein and hepatic artery interactions in porcine liver. Am J Physiol. 1994;267:H1233-H1242.
4. Shibayama Y, Nakata K. The relation of periportal fibrosis to portal hypertension. J Hepatol. 1990;11:313-317.
5. Shibayama Y, Nakata K. Localization of increased hepatic vascular resistance in liver cirrhosis. Hepatology. 1985;5:643-648.
6. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol. 2000;32(suppl 1):141-156.
7. Grossman HJ, Grossman VL, Bhathal PS. The effect of hepatocyte enlargement on the hemodynamic characteristics of the isolated perfused rat liver preparation. Hepatology. 1998;27:446-451.
8. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38(suppl 1):S54-S68.
9. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325-337.
10. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233-240.
11. Gasull X, Bataller R, Gines P, et al. Human myofibroblastic hepatic stellate cells express Ca(2+)-activated K(+) channels that modulate the effects of endothelin-1 and nitric oxide. J Hepatol. 2001;35:739-748.
12. Rockey DC. Vascular mediators in the injured liver. Hepatology. 2003;37:4-12.
13. Bataller R, Gasull X, Gines P, et al. In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology. 2001;33:956-962.
14. 2+ dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol. 2007;292:G556-G564.
15. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478-491.
16. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;46:927-934.
17. Tieche S, De Gottardi A, Kappeler A, et al. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol. 2001;34:38-45.
18. Bauer M, Zhang JX, Bauer I, et al. ET-1 induced alterations of hepatic microcirculation: sinusoidal and extrasinusoidal sites of action. Am J Physiol. 1994;267:G143-G149.
19. Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis. 1999;19:383-396.
20. Graupera M, Garcia-Pagan JC, Titos E, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology. 2002;122:387-393.
21. Graupera M, Garcia-Pagan JC, Abraldes JG, et al. Cyclooxygenasederived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology. 2003;37:172-181.
22. Titos E, Claria J, Bataller R, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology. 2000;119:794-805.
23. Graupera M, March S, Engel P, et al. Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol. 2005;288:G763-G770.
24. Zhou Q, Hennenberg M, Trebicka J, et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut. 2006;55:1296-1305.
25. Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28:926-931.
26. Fiorucci S, Antonelli E, Mencarelli A, et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology. 2005;42:539-548.
27. Mittal MK, Gupta TK, Lee FY, et al. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol. 1994;267:G416-G422.
28. Pastor CM, Hadengue A. Shear stress modulates the vascular tone in perfused livers isolated from normal rats. Hepatology. 2000;32:786-791.
29. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117:1222-1228.
30. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl. 2003;4:33-40.
31. Laleman W, Omasta A, Van de Casteele M, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology. 2005;42:1382-1390.
32. Matei V, Rodriguez-Vilarrupla A, Deulofeu R, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology. 2006;44:44-52.
33. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, et al. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology. 2002;36:381-385.
34. Loureiro-Silva MR, Iwakiri Y, Abraldes JG, et al. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol. 2006;44:886-893.
35. Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol. 1985;249:G549-G556.
36. Mucke I, Richter S, Menger MD, et al. Significance of hepatic arterial responsiveness for adequate tissue oxygenation upon portal vein occlusion in cirrhotic livers. Int J Colorectal Dis. 2000;15:335-341.
37. Richter S, Mucke I, Menger MD, et al. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol. 2000;279:G454-G462.
38. Schneider AW, Kalk JF, Klein CP. Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. J Hepatol. 1999;30:876-881.
39. Zipprich A, Loureiro-Silva MR, D'Silva I, et al. The effect of hepatic arterial blood flow changes on portal and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. J Hepatol. 2006;44:S96.
40. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43:S121-S131.
41. Takasaki S, Hano H. Three-dimensional observations of the human hepatic artery (arterial system in the liver). J Hepatol. 2001;34:455-466.
42. Loureiro-Silva MR, Cadelina GW, Groszmann RJ. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol. 2003;284:G567-G574.
43. Yang W, Benjamin IS, Moore K, et al. The action of nitric oxide on hepatic haemodynamics during secondary biliary cirrhosis in the rat. Eur J Pharmacol. 2003;461:41-48.
44. Zipprich A, Loureiro-Silva MR, Groszmann RJ. In CCl4-cirrhotic but not in BDL-cirrhotic rats nitric oxide is the main modulator of a decreased hepatic arterial vascular resistance. Hepatology. 2006;44:359A.
45. Lautt WW, Legare DJ, d'Almeida MS. Adenosine as putative regulator of hepatic arterial flow (the buffer response). Am J Physiol. 1985;248:H331-H338.
46. Mathie RT, Alexander B. The role of adenosine in the hyperaemic response of the hepatic artery to portal vein occlusion (the 'buffer response'). Br J Pharmacol. 1990;100:626-630.
47. Mathie RT, Alexander B, Ralevic V, et al. Adenosine-induced dilatation of the rabbit hepatic arterial bed is mediated by A2-purinoceptors. Br J Pharmacol. 1991;103:1103-1107.
48. Klotz KN. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:382-391.
49. Bryan PT, Marshall JM. Adenosine receptor subtypes and vasodilatation in rat skeletal muscle during systemic hypoxia: a role for A1 receptors. J Physiol. 1999;514(Pt 1):151-162.
50. Bryan PT, Marshall JM. Cellular mechanisms by which adenosine induces vasodilatation in rat skeletal muscle: significance for systemic hypoxia. J Physiol. 1999;514(Pt 1):163-175.
51. Vachiery F, Moreau R, Hadengue A, et al. Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alteration. J Hepatol. 1997;27:492-495.
52. Moreau R, Lee SS, Soupison T, et al. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. J Hepatol. 1988;7:98-105.
53. Zipprich A, Iwakiri Y, Ripoll C, et al. Nitric oxide is a mediator of the adenosine-induced vasodilatation of the hepatic artery in CCl-cirrhotic rats. J Hepatol. 2007;46:S89.
54. Fiorucci S, Antonelli E, Brancaleone V, et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol. 2003;39:932-939.
55. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, et al. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol. 2003;39:940-946.
56. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl(4) cirrhotic rats. J Hepatol. 2007;46:1040-1046.
57. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126:749-755.
58. Laleman W, Van Landeghem L, Van der Elst I, et al. Nitro-flurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007;132:709-719.
59. Kleber G, Steudel N, Behrmann C, et al. Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. Gastroenterology. 1999;116:906-914.
60. Zipprich A, Steudel N, Behrmann C, et al. Functional significance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology. 2003;37:385-392.
61. Zipprich A, Meiss F, Steudel N, et al. 13C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin content and oxygen supply. Aliment Pharmacol Ther. 2003;17:1559-1562.